Danaher Plans AI Lab for Antibody Discovery in 2027
Danaher plans to launch an AI-powered autonomous laboratory at Abcam, combining robotics and technology from across the company to design, build and test antibodies and other molecular tools. Expected to operate at scale in early 2027, the lab aims to accelerate discovery up to eightfold and eventually produce nearly ten times more reagents, while scientists retain key decision-making roles.
Tech · 10 sources · 8hRead itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About Abcam
Abcam Limited is a producer, distributor and seller of protein research tools operating worldwide from 13 locations with 1,800 employees of which 400 work in Research and Development (R&D). Abcam was listed on the Nasdaq and the London Stock Exchange until it was acquired by Danaher Corporation in 2023.
Everything about Abcam →- Country
- United Kingdom
- Headquarters
- Cambridge
- Inception
- 1998
- Website
- https://www.abcam.com/en-us